The Largest Biotechnology convention attracts over 15,000 participants and covers the wide spectrum of life science innovations and application areas.
NYGC's Founding Executive Director, Nancy J. Kelley, JD, MPP will be participating in a panel entitled -- The New Rules of Patient Engagement: The role of patient influence in driving novel partnerships and business models Monday, June 18th 10:00AM - 11:30AM
- Moderator: Jeffrey Greene, Global Transactions Leader, Life Sciences, Ernst & Young
- Speaker 1: Nancy Kelley, JD, MPP, Founding Executive Director, NY Genome Center
- Speaker 2: Robert F. Prachar, Jr., Senior Vice President, Enterprise Strategy and Portfolio Planning, Endo Pharmaceuticals
- Speaker 3: Bill Tulskie, PhD, CEO, HealthcareIT, Inc.
Panel Description: The life sciences industry is in the midst of a transformation commonly referred to as Pharma 3.0, under which companies will need to shift from producing new medicines to demonstrating improvements in health outcomes and creating innovative business models. This evolution is driven by rapid advancements in healthcare technology and the coming to a head of healthcare’s lack of sustainability globally.1,2
Inherent for success in this new healthcare ecosystem will be the ability of companies to reinvent their business models to make them more patient-centric and able to meet the demands of a patient-empowered, data-driven, outcomes-focused future in healthcare.
Companies seeking to find sustainable success in Pharma 3.0 currently face many key challenges and questions.
What changes would we need to enact to truly engage the patient and become better informed about the patient earlier in the R&D process? How can we leverage the vast pools of patient health data available to obtain insights about the safety and efficacy of their products and advance personalized medicine approaches to disease? Will earlier involvement better reflect patient priorities and needs in companies’ pipelines? How can we collaborate with non-traditional players that are increasingly targeting and investing in healthcare?
This panel will examine these questions and offer practical insights for companies seeking new approaches to drive their business model innovation. Panellists will offer their first hand experiences on how they have embraced new models to build relationships with their customers, utilized real world patient data in early stage clinical development and engaged in radical collaborations with health organizations and new entrants in healthcare to develop outcomes-focused offerings.
for more information: http://convention.bio.org/